• May 13, 2016

    On 10/05/2016, the BDA successfully completed within the specified period the first decentralised procedure (DCP) for marketing authorisation of medicinal products for which Bulgaria is the Reference Member State (RMS). A team of experts from the BDA assessed the documentation, in connection with the Marketing Authorisation of medicinal products Tamayra 5 mg/5 mg hard capsules […]

  • January 22, 2016

    Levor 5 mg/ml infusion solution is a medicinal product of Tchaikapharma High Quality Medicines Inc., for which the Bulgarian Drug Agency issued a marketing authorisation in January 2016. The active substance is levofloxacin as levofloxacin hemihydrate. Levor should be used in adults for treatment of the following infections: Community acquired pneumonia; Complicated skin and soft-tissue […]

  • The Bulgarian Drug Agency issued a marketing authorisation for the medicinal product Cisaxa 2mg/ml injection/ infusion solution. The medicine is a neuromuscular blocking agent with average duration of action for intravenous administration with quantitative composition cisatracurium 2 mg (as cisatracurium besilate 2.68 mg per 1 ml). Cisaxa should be used during surgical and other procedures […]

  • January 4, 2016

    The Bulgarian Drug Agency has issued a marketing authorisation for the medicinal product Remifentanil-Tchaikapharma 1 mg, 5 mg powder for concentrate for solution for injection/infusion, containing the active substance remifentanil and belonging to a group of medicines known as opiates. Remifentanil-Tchaikapharma is used together with other medicines called anaesthetics to: Facilitate falling asleep before surgery; […]

  • Tchaikapharma High Quality Medicines Inc. has obtained a new marketing authorisation for the medicinal product Coolsart – 20 mg/12.5 mg, 20 mg/25 mg, 40 mg/12.5 mg, 40 mg/25 mg film-coated tablets. Coolsart contains two active substances: olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension). Olmesartan medoxomil belongs to the group […]

  • In December 2015 Tchaikapharma High Quality Medicines Inc. was issued a new marketing authorisation by the Bulgarian Drug Agency for the medicinal product Olsart  10 mg, 20 mg, 40 mg film-coated tablets. The medicine contains the active substances olmesartan medoxomil and belongs to a group of medicines called angiotensin-II-receptor antagonists. They lower blood pressure by […]

  • November 4, 2015

    The Bulgarian Drug Agency issued a Marketing Authorisation for a new medicinal product of Tchaikapharma High Quality Medicines Inc. – Aripipa 15 mg tablets – containing the active substance aripiprazole. The medicinal product belongs to a group of drugs called antipsychotics. It is used for treatment of adults and adolescents above 15 years old, suffering […]

  • October 22, 2015

    Tchaikapharma High Quality Medicines Inc. has received new Marketing Authorization for Esomeprazole-Tchaikapharma 40 mg powder for injection / infusion solution. The product contains the active ingredient esomeprazole and belongs to a group of medicines called “proton pump inhibitors”. They work by reducing the amount of acid that the stomach produces. Esomeprazole-Tchaikapharma is used for short-term […]

  • Tchaikapharma High Quality Medicines Inc. has received marketing authorization for the medicinal product Dexketoprofen-Tchaikapharma of 50 mg / 2 ml solution for injection or concentrate for solution for infusion. The product is a pain relieving medicine from the group of the so called Nonsteroidal anti-inflammatory drugs (NSAIDs). It is used for the treatment of acute, […]

  • November 4, 2014

    Медикаментът е с най-изгодна цена за месечна терапия с инхиботор на протонната помпа – 9.75 лв. За всички останали продукти от същия терапевтичен клас пациентът трябва да доплати за месечно лечение между 11 лв. и 46 лв.